All News
Filter News
Found 808,857 articles
-
Early Identification of Acute Pulmonary Embolism Identified with EarlySense Technology Presented in Clinical Poster Presentation
5/20/2020
Case Study Published in JAMDA and Presented at AMDA Highlights How Early Warning Indications Allow Staff to Identify Acute Changes of Condition For Preventative Action [20-May-2020] WOBURN, Massachusetts , May 20, 2020 / PRNewswire/ -- EarlySense , the global leader in contact-free, continuous monitoring solutions for the healthcare continuum, announced tha
-
TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results
5/20/2020
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its fourth quarter and fiscal year ended March 31, 2020.
-
TruGenomix Partners With BlueBee to Create the Next Generation Behavioral Science Data Ecosystem
5/20/2020
The unprecedented COVID-19 crisis has unleashed global emotional trauma that is rapidly evolving into a mental health pandemic within the pandemic.
-
Focusing on the Genes that Matter Most: 10x Genomics Launches Targeted Gene Expression SolutionNew solution accelerates research validation in cancer, immunology and drug discovery
5/20/2020
Building on its earlier reveal at the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG) today launched its Targeted Gene Expression Solution for single cell and shortly following for spatial genomic research.
-
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5/20/2020
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per
-
Merck Manuals Survey: 8 in 10 Medical Students Say COVID-19 and Remote Learning Have Impacted Their Study Habits
5/20/2020
The ongoing COVID-19 pandemic is having a significant impact on medical students. As universities have shifted to virtual learning models and online classes, students have had to shift their learning and study habits.
-
Agilent Announces Cash Dividend of 18 Cents Per Share
5/20/2020
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on July 22, 2020, to all shareholders of record as of the close of business on June 30, 2020.
-
Smith+Nephew launches new JOURNEY™ II Unicompartmental Knee System
5/20/2020
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the launch of its new JOURNEY II Unicompartmental Knee (UK) System
-
FDA Approves Emergency Use of A&R Tarpaulins’ Patient Isolation Transportation Unit (PITU)
5/20/2020
AR Tech, a division of A&R Tarpaulins Inc., an aerospace and medical equipment manufacturer, received emergency approval for the use of its Patient Isolation Transportation Unit (PITU) by the Food and Drug Administration
-
Volpara Solutions Signs Collaboration Agreement with Ambry Genetics
5/20/2020
Volpara Health Technologies announced today that its subsidiary company, Volpara Solutions, has signed a collaboration agreement with Ambry Genetics®, one of the world's leading genetic testing companies.
-
scPharmaceuticals Inc. Announces Proposed Underwritten Public Offering of Common Stock
5/20/2020
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has commenced an underwritten public offering of shares of its common stock.
-
Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation
5/20/2020
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive f
-
VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
5/20/2020
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underw
-
BIOQUAL Announces Release of Two COVID-19 Research Publications
5/20/2020
BIOQUAL announces the release of two research publications in Science Magazine of our non-human primate model development efforts and our first successful testing of a COVID-19 vaccine candidate
-
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
5/20/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC)
-
Quest Analytics Names Steve Levin as Chief Executive Officer
5/20/2020
Quest Analytics, the leader in measuring, managing and monitoring health plan network performance, announced today that it has named Steve Levin as Chief Executive Officer, effective immediately
-
BioLab Sciences Partners with Red One Medical to Provide Transformative Wound Healing Products to Veterans and Active Military
5/20/2020
BioLab Sciences , a regenerative biotechnology company, today announced a partnership with Red One Medical that will help veterans and active military members access breakthrough wound healing and regenerative medicine. Red One Medical is private sector innovation partner of Department of Veterans Affairs (VA) and Department of Defense (DoD) hospitals. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), it provides
-
Medical Device Innovation Consortium Seeks Public Comment on In Vitro Diagnostics Real-World Evidence Framework
5/20/2020
The Medical Device Innovation Consortium (MDIC) is seeking public comment on its draft framework, Real-World Clinical Evidence Generation: Advancing Regulatory Science and Patient Access for In Vitro Diagnostics (IVDs).
-
Bioscience Association Manitoba Applauds Selfless Efforts of Frontline Workers
5/20/2020
Bioscience Association Manitoba (BAM) extends a thank you to the frontline workers across the province to acknowledge their efforts during this time.
-
Pathnostics Launches COVID-19 PCR Laboratory Test Designed to Detect Acute Infection
5/20/2020
Pathnostics, a diagnostic solutions company, today announced that it has launched a COVID-19 polymerase chain reaction (PCR) laboratory test designed to support U.S. health care workers in their efforts to keep their patients, colleagues and workplaces safe.